HomeHealthAccord Healthcare Launches Zubsolv® Buprenorphine and Naloxone Sublingual Tablets

Accord Healthcare Launches Zubsolv® Buprenorphine and Naloxone Sublingual Tablets

Accord Healthcare is committed to helping improve the lives of people living with addiction in Ireland. Accord understands the ongoing challenges and complexities experienced by both people living with addiction and their treating physicians.

Thus, he is committing his expertise and patient-centered approach to providing addiction treatment, and Zubsolv® it will be the first of these addiction-focused treatments to be launched in Ireland.

Zubsolv® is a sublingual tablet containing the active substances buprenorphine and naloxone, and Accord will launch five strengths across the range (1.4/0.36 mg, 2.9/0.71 mg, 5.7/1.4 mg, 8.6/2.1mg and 11.4/2.9mg).

This medicine is used for the treatment of dependence on opioid drugs -such as heroin or morphine- in adults and adolescents over 15 years of age who have agreed to be treated for their addiction, and who are also receiving medical, social and psychological support.1

Padraic O’Brien, Accord Healthcare Ireland MD. Photo: David Jones

“Addiction remains a challenging area for patients and doctors in Ireland,” says Padraic O’Brien, MD of Accord Healthcare Ireland. “The scale and cost of addiction to society is enormous, and substance addiction is one of the leading causes of global disability in young people. At Accord Healthcare, we are committed to addressing public health priorities through the development and distribution of high-quality medicines. We are now putting our experience and scale behind addiction to help improve the status quo.

“Our vision is to stand shoulder to shoulder with patient groups and professionals as a long-term partner in addiction management.”

The Misuse of Drugs Regulations 2017 entered into force in Ireland on November 22, 2017. The purpose of these regulations is to provide access to certain buprenorphine-based medicines in opioid substitution treatment (including buprenorphine/naloxone and buprenorphine only) on the same legal basis as methadone.

Accord Zubsolv® will be available under this program and through United Drug.

For more information contact Accord in Cork on 021 461 9040. Please see the Summary of Product Characteristics (SPC) for more information. The SPC will be available on the website of the Health Products Regulatory Authority www.hpra.es and for healthcare professionals on the Accord Healthcare website www.accord-healthcare.ie.

References available upon request.

Source link

- Advertisment -